Nkarta, Inc. (NASDAQ:NKTX – Get Rating) was the recipient of a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 5,580,000 shares, an increase of 33.2% from the May 15th total of 4,190,000 shares. Based on an average daily volume of 2,920,000 shares, the days-to-cover […]
Nkarta (NASDAQ:NKTX – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Saturday, Zacks.com reports. According to Zacks, “Nkarta Inc. is a biopharmaceutical company. It develops and commercializes cell therapies for cancer treatment. The company’s product candidate includes NKX101 and NKX019, which are […]
Nkarta (NASDAQ:NKTX – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday, Zacks.com reports. The firm presently has a $15.00 price target on the stock. Zacks Investment Research‘s price objective indicates a potential upside of 14.68% from the company’s current price. […]
Zacks Investment Research upgraded shares of Nkarta (NASDAQ:NKTX – Get Rating) from a hold rating to a buy rating in a report issued on Wednesday, Zacks.com reports. Zacks Investment Research currently has $13.00 price objective on the stock. According to Zacks, “Nkarta Inc. is a biopharmaceutical company. It develops and commercializes cell therapies for cancer […]